BACKGROUND: Outcomes are suboptimal in ulcerative colitis (UC). Telemedicine for UC is feasible and improves outcomes. Our goals were to evaluate a home telemanagement system for UC (UC HAT) on disease activity, quality of life (QoL), and adherence compared to best available care (BAC) in a randomized, controlled trial. METHODS:Adults with UC were randomly assigned to receive UC HAT or BAC for 12 months. UC HAT recruits answered questions regarding disease activity, adherence, side effects, and measured their weight weekly. An educational curriculum was delivered after each session. Alerts and action plans were generated based on the results. BAC underwent routine follow-up, received written action plans, and were given educational fact sheets. Seo Index scores, Inflammatory Bowel Disease Questionnaire (IBDQ) scores, and adherence rates were compared between UC HAT and BAC at 1 year. RESULTS:Twenty-five patients were randomized to UC HAT and 22 to BAC. After 12 months, 11 withdrew in UC HAT compared to 5 in BAC. Disease activity, QoL, and adherence were not different between groups at any timepoint postbaseline. Adjusted analyses of trial completers using all available data demonstrated decreased Seo Index (11.9 in UC HAT (P = 0.08) versus 1.2 in BAC (P = 0.84) and increased IBDQ scores (12.5 in UC HAT (P = 0.04) versus to -3.8 in BAC (P = 0.47) from baseline in UC HAT compared to BAC. CONCLUSIONS:UC HAT did not improve disease activity, QoL, or adherence compared to BAC after 1 year. After adjustment for baseline disease knowledge, UC HAT trial completers experienced significant gains in disease-specific QoL from baseline compared to BAC trial completers. Our results suggest a potential benefit of UC HAT. Further research is indicated to determine if telemedicine improves outcomes in patients with IBD.
RCT Entities:
BACKGROUND: Outcomes are suboptimal in ulcerative colitis (UC). Telemedicine for UC is feasible and improves outcomes. Our goals were to evaluate a home telemanagement system for UC (UC HAT) on disease activity, quality of life (QoL), and adherence compared to best available care (BAC) in a randomized, controlled trial. METHODS: Adults with UC were randomly assigned to receive UC HAT or BAC for 12 months. UC HAT recruits answered questions regarding disease activity, adherence, side effects, and measured their weight weekly. An educational curriculum was delivered after each session. Alerts and action plans were generated based on the results. BAC underwent routine follow-up, received written action plans, and were given educational fact sheets. Seo Index scores, Inflammatory Bowel Disease Questionnaire (IBDQ) scores, and adherence rates were compared between UC HAT and BAC at 1 year. RESULTS: Twenty-five patients were randomized to UC HAT and 22 to BAC. After 12 months, 11 withdrew in UC HAT compared to 5 in BAC. Disease activity, QoL, and adherence were not different between groups at any timepoint postbaseline. Adjusted analyses of trial completers using all available data demonstrated decreased Seo Index (11.9 in UC HAT (P = 0.08) versus 1.2 in BAC (P = 0.84) and increased IBDQ scores (12.5 in UC HAT (P = 0.04) versus to -3.8 in BAC (P = 0.47) from baseline in UC HAT compared to BAC. CONCLUSIONS: UC HAT did not improve disease activity, QoL, or adherence compared to BAC after 1 year. After adjustment for baseline disease knowledge, UC HAT trial completers experienced significant gains in disease-specific QoL from baseline compared to BAC trial completers. Our results suggest a potential benefit of UC HAT. Further research is indicated to determine if telemedicine improves outcomes in patients with IBD.
Authors: Victor M Montori; Pamela K Helgemoe; Gordon H Guyatt; Diana S Dean; Teresa W Leung; Steven A Smith; Yogish C Kudva Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: Charlene C Quinn; Suzanne Sysko Clough; James M Minor; Dan Lender; Maria C Okafor; Ann Gruber-Baldini Journal: Diabetes Technol Ther Date: 2008-06 Impact factor: 6.118
Authors: Charlene C Quinn; Ann L Gruber-Baldini; Michelle Shardell; Kelly Weed; Suzanne S Clough; Malinda Peeples; Michael Terrin; Lauren Bronich-Hall; Erik Barr; Dan Lender Journal: Contemp Clin Trials Date: 2009-02-27 Impact factor: 2.226
Authors: Aaron Yarlas; Stephen Maher; Martha Bayliss; Andrew Lovley; Joseph C Cappelleri; Andrew G Bushmakin; Marco D DiBonaventura Journal: J Patient Cent Res Rev Date: 2020-04-27